MX2023002156A - Acido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentan o-1-carboxilico y derivados del mismo para su uso en el tratamiento de enfermedades de las vias respiratorias. - Google Patents

Acido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentan o-1-carboxilico y derivados del mismo para su uso en el tratamiento de enfermedades de las vias respiratorias.

Info

Publication number
MX2023002156A
MX2023002156A MX2023002156A MX2023002156A MX2023002156A MX 2023002156 A MX2023002156 A MX 2023002156A MX 2023002156 A MX2023002156 A MX 2023002156A MX 2023002156 A MX2023002156 A MX 2023002156A MX 2023002156 A MX2023002156 A MX 2023002156A
Authority
MX
Mexico
Prior art keywords
treatment
airway diseases
phenylthiazol
cyclopentane
carbamoyl
Prior art date
Application number
MX2023002156A
Other languages
English (en)
Spanish (es)
Inventor
Gómez Juan Camacho
Palomino Laria Julio Castro-
Laria Nahomi Castro-Palomino
Álvarez Alina Ariosa
Original Assignee
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma Sl filed Critical Palobiofarma Sl
Publication of MX2023002156A publication Critical patent/MX2023002156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MX2023002156A 2020-08-21 2021-08-20 Acido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentan o-1-carboxilico y derivados del mismo para su uso en el tratamiento de enfermedades de las vias respiratorias. MX2023002156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (1)

Publication Number Publication Date
MX2023002156A true MX2023002156A (es) 2023-03-01

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002156A MX2023002156A (es) 2020-08-21 2021-08-20 Acido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentan o-1-carboxilico y derivados del mismo para su uso en el tratamiento de enfermedades de las vias respiratorias.

Country Status (20)

Country Link
US (1) US20230321053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3957308A1 (cg-RX-API-DMAC7.html)
JP (1) JP7794807B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230054444A (cg-RX-API-DMAC7.html)
CN (1) CN115942933A (cg-RX-API-DMAC7.html)
AU (1) AU2021327728B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002778A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190081A1 (cg-RX-API-DMAC7.html)
DK (1) DK4199922T3 (cg-RX-API-DMAC7.html)
ES (1) ES3001104T3 (cg-RX-API-DMAC7.html)
FI (1) FI4199922T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069338T2 (cg-RX-API-DMAC7.html)
LT (1) LT4199922T (cg-RX-API-DMAC7.html)
MX (1) MX2023002156A (cg-RX-API-DMAC7.html)
PL (1) PL4199922T3 (cg-RX-API-DMAC7.html)
PT (1) PT4199922T (cg-RX-API-DMAC7.html)
RS (1) RS66263B1 (cg-RX-API-DMAC7.html)
SI (1) SI4199922T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022038261A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001881A2 (en) * 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2331220B1 (es) 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
AU2015315628A1 (en) * 2014-09-08 2017-04-20 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska

Also Published As

Publication number Publication date
JP2023538419A (ja) 2023-09-07
AU2021327728B2 (en) 2026-06-11
PL4199922T3 (pl) 2025-02-10
WO2022038261A1 (en) 2022-02-24
DK4199922T3 (da) 2024-11-25
CA3190081A1 (en) 2022-02-24
KR20230054444A (ko) 2023-04-24
RS66263B1 (sr) 2024-12-31
EP3957308A1 (en) 2022-02-23
BR112023002778A2 (pt) 2023-03-14
HRP20241621T1 (hr) 2025-01-31
CN115942933A (zh) 2023-04-07
SI4199922T1 (sl) 2025-03-31
US20230321053A1 (en) 2023-10-12
PT4199922T (pt) 2024-12-18
AU2021327728A1 (en) 2023-03-09
LT4199922T (lt) 2025-01-10
EP4199922A1 (en) 2023-06-28
EP4199922B1 (en) 2024-09-25
JP7794807B2 (ja) 2026-01-06
ES3001104T3 (es) 2025-03-04
FI4199922T3 (fi) 2024-12-05
HUE069338T2 (hu) 2025-02-28

Similar Documents

Publication Publication Date Title
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
RU2010108640A (ru) Новая комбинация терапевтических агентов
JP2018513107A5 (cg-RX-API-DMAC7.html)
JP2014525471A (ja) 咳および咳発作の治療
AU2008241045C1 (en) Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma
BR112023002778A2 (pt) Ácido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il) carbamoil) ciclopentano-1-carboxílico e derivados do mesmo para uso no tratamento de doenças das vias aéreas
JP2021531299A5 (cg-RX-API-DMAC7.html)
JP2023538419A5 (cg-RX-API-DMAC7.html)
JP2014237666A (ja) アルホルモテロール及びチオトロピウムの組成物及びその使用方法
WO2024192149A3 (en) Method of treating enterovirus in chronic obstructive pulmonary disease patients
JP2024520650A (ja) 特発性肺線維症の処置におけるカプサイシン誘導体
JP2019519572A (ja) Copdを処置するための組成物および方法
WO2023156808A3 (en) Compositions and methods for treating pulmonary disorders
JP2013511528A (ja) 喘息の急性憎悪の治療及びそれに罹患した患者の入院の可能性の低減
JP6021952B2 (ja) 慢性閉塞性肺疾患の治療法
KR20090046746A (ko) 만성 폐쇄성 폐 질환을 치료하기 위한 에르도스테인 및 베타-2 작용제의 조합물
WO2025250560A1 (en) Methods for treating bronchiectasis
WO2026099600A1 (en) Alvelestat in the treatment of non-cystic fibrosis bronchiectasis
WO2026052051A1 (zh) 杂环化合物在治疗肺疾病中的应用
JP2022532518A (ja) 神経障害性疼痛の治療のための医薬組成物
WO2010047295A1 (ja) 帯状疱疹関連痛の予防又は治療薬
US20210128496A1 (en) Dropropizine in combination with ambroxol in the dosage form of syrup or tablets